We are live on ! Find out more
GNMX

Aevi Genomic Medicine Inc
GNMX

Delisted

GNMX was delisted on the 3rd of February, 2020.

Back to rankings

45 hedge funds and large institutions have $14.6M invested in Aevi Genomic Medicine Inc in 2017 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 9 increasing their positions, 12 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

16% more capital invested

Capital invested by funds: $12.6M → $14.6M (+$2M)

8% less funds holding

Funds holding: 49 → 45 (-4)

25% less repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 12

30% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 10

Holders
45
Holders Change
-4
Holders Change %
-8.16%
% of All Funds
1.02%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
9
Reduced
12
Closed
10
Calls
$12K
Puts
–
Net Calls
+$12K
Net Calls Change
+$13K

Top Buyers

Rank Fund Capital Flow
1
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$4.64M
2
Renaissance Technologies
Renaissance Technologies
New York
+$107K
3
VAM
Verity Asset Management
North Carolina
+$19.8K
4
Wells Fargo
Wells Fargo
California
+$18.4K
5
Citadel Advisors
Citadel Advisors
Florida
+$14.7K

Top Sellers

Rank Fund Capital Flow
1
BBA
Baker Bros. Advisors
New York
-$671K
2
Vanguard Group
Vanguard Group
Pennsylvania
-$278K
3
2L
22NW LP
Washington
-$195K
4
NCMW
Northern Capital Management (Wisconsin)
Wisconsin
-$192K
5
EMG
ETF Managers Group
New Jersey
-$74K
Name Holding Trade Value Shares
Change 		Change in
Stake
Adage Capital Partners
1
Adage Capital Partners
Massachusetts
$6.6M +$4.64M +3,400,000 +162%
BBA
2
Baker Bros. Advisors
New York
$4.87M -$671K -491,284 -11%
Vanguard Group
3
Vanguard Group
Pennsylvania
$911K -$278K -203,972 -21%
BlackRock
4
BlackRock
New York
$890K +$4.22K +3,092 +0.4%
Geode Capital Management
5
Geode Capital Management
Massachusetts
$201K -$22.2K -16,242 -9%
Wells Fargo
6
Wells Fargo
California
$172K +$18.4K +13,500 +10%
BC
7
Birchview Capital
Vermont
$154K – – –
Renaissance Technologies
8
Renaissance Technologies
New York
$112K +$107K +78,400 +516%
Millennium Management
9
Millennium Management
New York
$104K -$58.5K -42,856 -33%
PAM
10
Panagora Asset Management
Massachusetts
$77K +$7.42K +5,433 +9%
Northern Trust
11
Northern Trust
Illinois
$66K -$6.88K -5,036 -8%
California Public Employees Retirement System
12
California Public Employees Retirement System
California
$61K – – –
Goldman Sachs
13
Goldman Sachs
New York
$57K -$55.4K -40,564 -46%
ARTA
14
A.R.T. Advisors
New York
$50K -$44.7K -32,764 -44%
Bank of New York Mellon
15
Bank of New York Mellon
New York
$34K – – –
Citadel Advisors
16
Citadel Advisors
Florida
$34K +$14.7K +10,752 +62%
VAM
17
Verity Asset Management
North Carolina
$28K +$19.8K +14,500 New
State Street
18
State Street
Massachusetts
$25K – – –
CDH
19
Charles D. Hyman
$18K – – –
Susquehanna International Group
20
Susquehanna International Group
Pennsylvania
$16K -$23.7K -17,329 -56%
Northwestern Mutual Wealth Management
21
Northwestern Mutual Wealth Management
Wisconsin
$12K +$13.7K +10,000 New
Morgan Stanley
22
Morgan Stanley
New York
$11K +$2.28K +1,669 +24%
OIA
23
OneDigital Investment Advisors
Kansas
$9K -$1.02K -750 -9%
UBS Group
24
UBS Group
Switzerland
$9K +$3.63K +2,660 +55%
Macquarie Group
25
Macquarie Group
Australia
$8K +$9.63K +7,058 New
1
2 3

GNMX Hedge Fund Activity: Q4 2017 in Review

45 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Aevi Genomic Medicine Inc (GNMX) for Q4 2017, worth a combined $14.6M — up 16% from $12.6M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of GNMX and 7 opened new positions — a net loss of 3 holders — while 12 trimmed existing stakes and 9 added.

The largest buyer was Adage Capital Partners, adding an estimated $4.64M. The largest seller was Baker Bros. Advisors, cutting an estimated $671K.

  • 45 institutional investors held Aevi Genomic Medicine Inc (GNMX) as of Q4 2017, down from 49 in Q3 2017.
  • Funds reported $14.6M of Aevi Genomic Medicine Inc stock for Q4 2017, up 16% quarter-over-quarter.
  • 7 funds opened new Aevi Genomic Medicine Inc positions in Q4 2017 and 10 closed out, a net change of -3 holders.
  • The largest Aevi Genomic Medicine Inc buyer in Q4 2017 was Adage Capital Partners, an estimated $4.64M added.
  • The largest Aevi Genomic Medicine Inc seller in Q4 2017 was Baker Bros. Advisors, an estimated $671K sold.

Based on aggregated 13F filings for Q4 2017.